Mr. Stephen S. Yoder joined Pieris as Chief Executive Officer in January 2010. Prior to joining Pieris, from July 2003 to December 2009 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. 

Mr. Thomas Bures joined Pieris Pharmaceuticals as the Vice President of Finance in December 2017. He has more than 20 years of finance experience and has spent the last several years managing finance organizations within the healthcare and life sciences industry. Mr. Bures joins the Company from Genocea Biosciences Inc. (NASDAQ: GNCA) where he served as the VP Corporate Controller since 2015 and was responsible for the financial reporting, accounting, tax, treasury and insurance functions. Before joining Genocea, Mr. Bures worked for five years at PAREXEL International Corporation (formerly listed on NASDAQ: PRXL), most recently as the VP Assistant Controller. He was responsible for financial reporting, internal controls, and GAAP and statutory accounting for all legal entities. He started his career in Ernst and Young’s audit practice in 1996 and served multinational clients in the retail, manufacturing and banking industries. Mr. Bures received his B.S. in Accountancy from the College of the Holy Cross.

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Dr. Olwill was Director of Research at Fusion Antibodies plc where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer-reviewed journals. Dr. Olwill received his PhD in Molecular Hematology/Oncology from the University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Dr. Olwill has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.